A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.
Also called NCT07613307
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 130 participants
- Sponsor
- Registry
-
NCT07613307
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- India, Saudi Arabia, South Africa, United Arab Emirates
- Registry status
- Recruiting
Technical summary
Registry record NCT07613307. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07-15 (actual); primary completion 2027-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
- Acronym
- ACHIEVE-RAM
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diabetes Melletus
- Condition
- Glucose Metabolism Disorders
- Condition
- Metabolic Disorders
- Condition
- Nutritional and Metabolic Diseases
- Condition
- Endocrine System Diseases
- Condition
- Feeding Behavior
- Condition
- Behavior
- Condition
- Fasting
- Condition
- Glucagon-Like Peptide-1 Receptor
- Condition
- Glucagon-Like Peptide Receptors
- Condition
- Receptors, G-Protein-Coupled
- Condition
- Receptors, Cell Surface
- Condition
- Membrane Proteins
- Condition
- Proteins
- Condition
- Receptors, Peptide
- Intervention (Drug)
- Orforglipron
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07613307- Content hash
ef90600f586931cdcbc18e5dd98efa996f53682ca11e029a73e32fe285fe8cbe